Leukogene Therapeutics Inc., a biopharmaceutical company developing next-generation therapies for hematologic and other immunologically “cold” malignancies, announced that it has received funding from the South Carolina Research Authority (SCRA) and its investment affiliate, SC Launch Inc.

“We are honored to receive this strategic funding from SCRA and SC Launch Inc. It will allow us to advance our programs toward the clinic, strengthen our position as a leader in developing next-generation cancer therapeutics, and continue building a world-class biotech company right here in South Carolina,” said Dr. Sandeep Gupta, Chief Executive Officer of Leukogene. 

“Leukogene Therapeutics exemplifies the kind of innovative, high-growth company that SCRA and SC Launch Inc. were designed to support,” said Matt Bell, Executive Director of SC Launch. 

Nathan Dolloff, PhD, Founder and Chief Scientific Officer, added, “This investment represents a strong validation of our vision and science and enables us to accelerate our mission of bringing transformative therapies to patients with hard-to-treat cancers.”